Health Catalyst (HCAT) Stock Price, News & Analysis

Company Overview

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.

Key Stats

• Today's Range: $3.61 to $3.89
• 50-Day Range: $3.70 to $5.55
• 52-Week Range: $3.56 to $9.24
• Volume: 465,545 shs
• Average Volume: 614,025 shs
• Market Capitalization: $269.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.36
• Consensus Rating: Moderate Buy

Health Catalyst Stock Analysis - MarketRank™

Health Catalyst scored higher than 88% of companies evaluated by MarketBeat, and ranked 80th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Health Catalyst has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Health Catalyst has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Health Catalyst are expected to grow in the coming year, from ($0.33) to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Health Catalyst is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Health Catalyst is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Health Catalyst has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.26% of the float of Health Catalyst has been sold short.

Short Interest Ratio / Days to Cover

Health Catalyst has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Health Catalyst has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Health Catalyst does not currently pay a dividend.

Dividend Growth

Health Catalyst does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -0.91

Percentage of Shares Shorted

5.26% of the float of Health Catalyst has been sold short.

Short Interest Ratio / Days to Cover

Health Catalyst has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Health Catalyst has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.27

News Sentiment

Health Catalyst has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Health Catalyst this week, compared to 4 articles on an average week.

MarketBeat Follows

3 people have added Health Catalyst to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Health Catalyst insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,906.00 in company stock.

Percentage Held by Insiders

Only 2.50% of the stock of Health Catalyst is held by insiders.

Percentage Held by Institutions

85.00% of the stock of Health Catalyst is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HCAT Stock Analysis - Frequently Asked Questions

How have HCAT shares performed this year?

Health Catalyst's stock was trading at $7.07 at the start of the year. Since then, HCAT shares have decreased by 45.7% and is now trading at $3.84.
View the best growth stocks for 2025 here.

How were Health Catalyst's earnings last quarter?

Health Catalyst, Inc. (NASDAQ:HCAT) released its earnings results on Wednesday, November, 6th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by $0.03. The company's revenue for the quarter was up 3.5% on a year-over-year basis.
Read the conference call transcript.

When did Health Catalyst IPO?

Health Catalyst (HCAT) raised $129 million in an initial public offering on Thursday, July 25th 2019. The company issued 6,000,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

Who are Health Catalyst's major shareholders?

Health Catalyst's top institutional shareholders include Nepsis Inc. (2.98%), SG Americas Securities LLC (0.12%), Dynamic Advisor Solutions LLC (0.06%) and Summit Global Investments (0.04%). Insiders that own company stock include Daniel D Burton, Bryan Truman Hunt, Kevin Lee Freeman, Daniel Lesueur, Benjamin Landry, Daniel H Orenstein, Jason Alger, Linda Llewelyn and Duncan Gallagher.
View institutional ownership trends.

How do I buy shares of Health Catalyst?

Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Health Catalyst own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Health Catalyst investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), Voyager Therapeutics (VYGR) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 4/19/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Computer programming, data processing, & other computer related
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:HCAT
• CIK: 1636422
• Web: www.healthcatalyst.com
• Phone: (801) 708-6800
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.36
• High Stock Price Target: $16.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +117.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-118,150,000.00
• Net Margins: -26.20%
• Pretax Margin: -26.25%
• Return on Equity: -7.51%
• Return on Assets: -3.72%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 1.41
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $306.58 million
• Price / Sales: 0.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.38 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 70,211,000
• Free Float: 59,327,000
• Market Cap: $269.61 million
• Optionable: Optionable
• Beta: 1.43